期刊文献+

2007~2010年我院住院患者抗菌药物的使用情况分析 被引量:3

Analysis of the Application of Antibacterials in Our Hospital from 2007 to 2010
下载PDF
导出
摘要 目的了解我院住院患者抗菌药物的使用情况,为临床合理使用抗菌药物提供参考。方法对我院2007~2010年HIS系统中各类抗菌药物销售金额利用Excel软件进行统计、分析及并对抗菌药物销售金额、构成比、DDDs值进行排序。结果我院使用的抗菌药物品种广泛,共涉及7类81种,β-内酰胺类占主导地位,其次为氟喹诺酮类和氨基糖苷类。结论我院的抗菌药物用药结构基本合理,抗菌药物用药品种趋向集中,但个别品种的应用缺乏合理性,建议临床医师根据病原学检查结果选用抗菌药物。 Objective To investigate the utilization status of antibacterials in our hospital and to provide reference for clinical rational use of antibacterials. Methods The data on antibacterials use in the hospital HIS system from 2007 to 2010 were collected and analyzed by Excel software, including drug consumption amount, the varieties of antibacterials and DDDs. Results The use of antibacterial drugs in our hospital wides variety, involving a total of 7 class 81, β-lactam antibiotics dominant, followed by fluoroquinolones and aminoglycosides. Conclusion The application of antibacterials in our hospital is rational in general and the varieties tend to concentrate, but the application of a few categories of antimicrobials is not reasonable. It is recommended that the clinician using antibiotics should be according to the etiological examination results.
出处 《中国现代医生》 2011年第30期44-46,共3页 China Modern Doctor
关键词 抗菌药物 使用情况 使用强度(DDDs) Antibacterials Use case DDDs
  • 相关文献

参考文献4

二级参考文献31

  • 1[2]Hiramatsu K,Okuma K,Ma XX,et al. New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin resistance in the community. Curr-Opin-Infect-Dis, 2002, 15(4):407~413
  • 2[3]Medical Letter. The choice of antibacterial drugs. Med Lett Drugs Ther, 1999,41:95
  • 3[4]Inaba Y, Hiramatsu K. Emergence of hetero-VISA strain in Japanese hospitals and its countermeasure. Nippon Rinsho, 1998,56(10):2699
  • 4[8]Wilhelm MP, Estes L. Vancomycin. Mayo Clin Proc 1999,74: 928 Hanaki H, Hiramatsu K. Combination effect of teicoplanin and various antibiotic against hetero-VRSA and VRSA. Kansenshogaku Zasshi, 1999,73(10): 1048
  • 5[10]Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin/dalfopritin in patients intolerant of or failing prior therapy. J Antimicrob Chemother,2000, 46:775~784
  • 6[11]Werner G, Klare I, Witte W. Association between quinupristin/dalfopristin resistance in glycopeptide-resistant Enterococcus faecium and the use of additives in animal feed. Eur J Clin Microbiol Infect Dis,1998, 17:401~402
  • 7[12]Rybak MJ. Therapeutic options for Gram- positive infections. J Hosp Infect, 2001,49(Supplement A):S25~S32
  • 8[13]Jones ME, Visser MR, Klootwijk M, et al. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, lfloxacin,sparfloxacin, and trovafloxacin and nonquinoloones linozelid,quinupristin/dalfopritin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother, 1999,43:421~423
  • 9[14]Zurenko GE, Yage BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.Antimicrob Ag Chemother, 1996, 40:839~845
  • 10[15]Rybak MJ, Herscberger E, Moldovan T, Grucz RG. In-vitro activities of daptomycin, vanconycin, linexolid and quinupristin/dalfopritin against staphylococci and enterococci, including vancomycinintermediate and -resistant strains. Antimicrob Ag Chemother, 2000,44:1062~1066

共引文献56

同被引文献12

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部